Lee Cronin

DeepMatter Group Plc is engaged in the development of a number of projects targeting new chemicals, materials, formulations, and pharmaceuticals in commercial areas. It operates through the following segments: DeepMatter and InfoChem. The DeepMatter segment owns, develops and is in the early stage of exploiting intellectual property, software, hardware and data analysis capabilities combined as a visionary, disruptive platform called DigitalGlassware, enabling step changes in productivity and discovery for scientists in the pharma and life science sectors. The InfoChem segment develops and commercialises cheminformatics software to handle, store and retrieve chemical structures and reactions for application in pharma, life sciences, and scientific publications. The company was founded by Jon-Paul Griffiths and Mark G. Moloney on June 13, 2006 and is headquartered in Glasgow, the United Kingdom.

Cronin 3D Ltd. provides 3D printing services. It develops a platform for the use of nanomaterials in pharmaceuticals through the use of 3D printing. The firm owns and operates a platform which is used in the discovery, optimization, and portable manufacture of small molecules and nanomaterials for the pharmaceutical, formulation, and materials science industries. The company is headquartered in Glasgow, the United Kingdom.

Chemify Ltd. is a company based in Glasgow, UK that leverages chemistry experience, hardware robotics, and artificial intelligence to provide an end-to-end workflow for drug discovery, molecule synthesis, and materials discovery. By digitizing chemistry, Chemify is reimagining chemical research, discovery, and manufacturing to benefit humanity by accelerating advances across chemistry, with a focus on medicine and functional materials. The British company was founded in 2019 by CEO Lee Cronin, who conceptualized advancements from his digital chemistry laboratory at the University of Glasgow.